Still getting better as they speak: strength that has continued or built past the reported period, tied to named live dr
The model's full reasoning — Q1 2017 call → NOWe need to determine if management conveys both halves: (1) strength extending past the reported period, and (2) a named, live driver behind it. From the transcript, management discusses Q1 results. They mention positive momentum in some areas. For example, regarding Pall: "We saw signs of stabilization across a number of our industrial and process end-markets. We were also encouraged by strong bookings throughout the quarter." That suggests strong bookings during the quarter, but does it indicate strength continuing after the quarter? The statement is about Q1 bookings. They also mention "strong bookings throughout the quarter" but not necessarily after quarter-end. Regarding Cepheid: "Cepheid is off to a great start and achieved double-digit core revenue growth in the quarter." They also say "we are very encouraged by this early progress." That's about Q1. Regarding Life Sciences: "Pall’s call revenue grew low-single-digits with mid-single-digit growth at Pall Life Sciences led by gain across our biopharmaceutical business, particularly in single use technologies." They mention strong bookings throughout the quarter for Pall. But again, that's during the quarter. Management does give guidance for Q2: "We are initiating second quarter adjusted diluted net EPS guidance between $0.95 and $0.98, which assumes second quarter core revenue growth comparable to the first quarter of 2017." That is guidance, not a statement about observed activity continuing. They also say "We continue to expect full-year 2017 adjusted diluted net earnings per share to be in the range of $3.85 to $3.95." That's forward-looking. Do they describe any activity after period-end? For example, they talk about "strong bookings throughout the quarter" for Pall, but not about bookings since the quarter ended. They mention "we saw signs of stabilization" but that's about the period. They also mention "We’re off to a good start in 2017" at the beginning, but that's overall. In the Q&A, there is discussion about Cepheid's growth. Tom Joyce says: "In terms of what’s driving that growth. It’s pretty well -- it’s pretty broad across the portfolio. Infectious disease, sexual health continues to perform quite well.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| CW | Curtiss-Wright Corporation | Q1 2024 | 2024-05-02 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CNA | CNA Financial Corporation | Q4 2022 | 2023-02-06 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| WHF | WhiteHorse Finance, Inc. | Q1 2022 | 2022-05-10 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| NGVT | Ingevity Corporation | Q4 2021 | 2022-02-25 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
| PRI | Primerica, Inc. | Q3 2016 | 2016-11-10 | B+ |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
GES · Q1 2017 → YESThe question is about whether management conveys that the business's positive momentum has continued or strengthened beyond the period being reported, tied to a named, already-live driver. YES Management describes continued strength in Europe retail comps into Q2 ("up in the low double digits... maintaining the strong momentum we have seen since the second half of last year") and ties it to a specific, live driver: improved traffic and conversion rates. The wholesale order book also finished up 3%, confirming 3% growth in orders already placed. Product improvements are explicitly named as the underlying driver ("we are having a more comprehensive collection... improve our comps by generating more traffic... improve the product that we are offering"). This meets both criteria for continuation beyond the reported period tied to a named live driver.
ILMN · Q1 2018 → YESThe question is about whether management conveys that the business's positive momentum has continued or strengthened beyond the reported period, tied to a named, already-live driver. YES Management describes the sequencing consumables business as having "very exciting" trajectory and "tremendous momentum" that is "still in place" into the rest of 2018, explicitly tied to observed drivers already generating revenue in Q1 (NovaSeq, NextSeq, microarray, consumer genomics, oncology) and 2018 activity such as "approaching 100 orders" for iSeq and "growing interest" in single-cell research. They raise guidance based on these continuing trends rather than forecasts alone, confirming the strength has extended past the reported period through live business activity.
WRB · Q1 2022 → YESThe question is: Does management convey that the business's positive momentum HAS CONTINUED OR STRENGTHENED BEYOND THE PERIOD BEING REPORTED, and tie that to at least one NAMED, ALREADY-LIVE driver? ...NO The transcript shows management expressing confidence in Q1 momentum (especially March and later-quarter submissions in specialty/E&S) and noting that "every day that we are writing business in 2022 that goes by" is positive, but this is framed as ongoing daily activity within the current year rather than observed strength beyond the 2022 Q1 close. The call is April 25, 2022, so any post-quarter commentary is limited to general market trajectory comments without specific post-period-end activity metrics.